ZYTIGA® (abiraterone acetate) Homeslider
STRONG TOGETHER
LET’S DO THIS

METASTATIC HIGH-RISK CSPC EFFICACY & SAFETY

  • LATITUDE Study Final Analysis
  • Efficacy endpoints
  • Safety Profile

CSPC = Castration-Sensitive Prostate Cancer

METASTATIC CRPC EFFICACY & SAFETY

  • Final analysis for COU-AA-302 and COU-AA-301 studies
  • Co-primary and secondary endpoint data
  • Established safety and tolerability profile
  • Discontinuation criteria

CRPC = Castration-Resistant Prostate Cancer

DOSING & MONITORING

  • Recommended dosage and administration
  • Dose modification guidelines
  • Patient monitoring considerations and schedule
DOSING & MONITORING

OR

RESOURCES

  • Comprehensive access support for your patients
  • Identifying cost support options
  • Helpful answers to common questions about ZYTIGA®